<DOC>
	<DOCNO>NCT00799942</DOCNO>
	<brief_summary>The purpose study investigate long-term safety , tolerability efficacy neramexane mesylate treatment congenital idiopathic nystagmus ( CIN ) . In addition , subgroup multiple sclerosis ( MS ) patient suffer acquire nystagmus include .</brief_summary>
	<brief_title>Open-lable Extension Study Safety Efficacy Neramexane Treat Congenital Acquired Nystagmus</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Nystagmus , Pathologic</mesh_term>
	<mesh_term>Nystagmus , Congenital</mesh_term>
	<criteria>patient succesfully complete leadin study MRZ 925790707/1 Occurence major treatmentemergent adverse event condition previous protocol ( MRZ 925790707/1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Nystagmus , congenital idiopathic</keyword>
</DOC>